文献速递新发突发、热带与寄生虫病

TAK-003登革热疫苗三年有效性与安全性

Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003).
PubMed 文献 · Clin Infect Dis · 2022-01-01

该探索性分析基于8个登革热流行国家4-16岁健康儿童(n=20099)的随机对照试验,按2:1接种TAK-003或安慰剂。三年累积对病毒学确诊登革热(VCD)有效性为62.0%,对住院VCD为83.6%;第三年VCD有效性降至44.7%,住院VCD仍维持70.8%,未发现重要安全风险。

要点

  • 三年累积对VCD有效性62.0%,对住院VCD有效性83.6%
  • 第三年VCD有效性降至44.7%,住院VCD仍达70.8%
  • 长期随访严重不良事件发生率疫苗组2.9%、安慰剂组3.5%,均与疫苗无关

核心结论

  • TAK-003在3年内对症状性登革热有效,有效性随时间下降,但对住院登革热的保护仍稳健,未发现重要安全风险。

研究设计与样本

  • 多国长期临床试验的探索性分析,健康4-16岁儿童n=20099,按2:1随机接受TAK-003或安慰剂,0、3月程序,全程进行基线血清状态检测和血清型特异性RT-PCR检测症状性登革热。

主要发现

  • 3年累积对VCD有效性62.0%(95%CI 56.6-66.7),对住院VCD 83.6%(95%CI 76.8-88.4)。
  • 基线血清阴性者对VCD有效性54.3%(95%CI 41.9-64.1)、对住院VCD 77.1%(95%CI 58.6-87.3);血清阳性者分别为65.0%(95%CI 58.9-70.1)和86.0%(95%CI 78.4-91.0)。
  • 第三年对VCD有效性降至44.7%(95%CI 32.5-54.7),对住院VCD维持70.8%(95%CI 49.6-83.0)。
  • 长期随访严重不良事件发生率TAK-003组2.9%、安慰剂组3.5%,均与疫苗无关。

临床怎么用

  • 提示临床关注该疫苗对住院登革热的持续保护,并注意第三年VCD有效性下降及加强针评估计划。

局限性

  • 本分析为探索性分析,摘要未报告各血清型分层有效性及长期随访的详细安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, we have reported its efficacy and safety in both seronegative and seropositive participants and that its performance varies by serotype, with some decline in efficacy from first to second year postvaccination. This exploratory analysis provides an update with cumulative and third-year data. METHODS: Healthy 4-16 year olds (n = 20099) were randomized 2:1 to receive TAK-003 or placebo (0, 3 month schedule). The protocol included baseline serostatus testing of all participants and detection of all symptomatic dengue throughout the trial with a serotype specific reverse transcriptase-polymerase chain reaction. RESULTS: Cumulative efficacy after 3 years was 62.0% (95% confidence interval, 56.6-66.7) against virologically confirmed dengue (VCD) and 83.6% (76.8-88.4) against hospitalized VCD. Efficacy was 54.3% (41.9-64.1) against VCD and 77.1% (58.6-87.3) against hospitalized VCD in baseline seronegatives, and 65.0% (58.9-70.1) against VCD and 86.0% (78.4-91.0) against hospitalized VCD in baseline seropositives. Efficacy against VCD during the third year declined to 44.7% (32.5-54.7), whereas efficacy against hospitalized VCD was sustained at 70.8% (49.6-83.0). Rates of serious adverse events were 2.9% in TAK-003 group and 3.5% in placebo group during the ongoing long-term follow-up (ie, second half of the 3 years following vaccination), but none were related. No important safety risks were identified. CONCLUSIONS: TAK-003 was efficacious against symptomatic dengue over 3 years. Efficacy declined over time but remained robust against hospitalized dengue. A booster dose evaluation is planned.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rivera L, Biswal S, Sáez-Llorens X, et al. Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003). Clin Infect Dis. 2022. PMID: 34606595. doi:10.1093/cid/ciab864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。